Alcon Buys Majority Stake in Aurion to Advance Eye Disease Treatment
Alcon acquired a majority interest in Aurion Biotech, a clinical-stage company developing advanced cell therapies to treat eye diseases. Terms of the deal weren't disclosed.
Investor's Business Daily on MSN1d
Alcon Sees Relative Strength Rating Climb To 73
Rating for Alcon jumped into a new percentile Tuesday, as it got a lift from 70 to 73. Please watch the video at ...
Zacks Investment Research on MSN1d
Alcon Stock Might Rise as Clareon Vivity IOL Secures CE Mark Approval
Alcon ALC recently announced that its Clareon Vivity intraocular lens (IOL), featuring extended depth of focus (EDOF) ...
Investing.com South Africa1d
BofA upgrades Alcon to "buy," citing earnings growth and product launches
Investing.com -- Alcon (SIX: ALCC) has received an upgrade to a "buy" rating from BofA Securities in a note dated Tuesday, signaling the beginning of an earnings growth cycle for the Swiss eye care ...
Alcon (ALC) Receives a Buy from Stifel Nicolaus
Stifel Nicolaus analyst Thomas Stephan maintained a Buy rating on Alcon (ALC – Research Report) today and set a price target of $100.00. The ...
Alcon Agrees to Acquire LENSAR, Inc.
Acquisition of ALLY Robotic Cataract Laser Systems strengthens Alcon’s cataract equipment and technology portfolio Next generation technology ...